Clinical Trial

Allogeneic CAR-T(CT0890B) in NKG2DL+ R/R AML

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
A Clinical Study to Investigate the Safety and Efficacy of CT0890B in Patients with Relapsed/Refractory Acute Myeloid Leukemia.
Trial Details
NCT Number NCT07617285
Lead Sponsor Peking University People's Hospital
Collaborators: CARsgen Therapeutics Co., Ltd.
Conditions AML, Refractory/Relapse Acute Myeloid Leukemia
Enrollment 27 participants
Start Date 2026-05-07
Primary Completion 2027-12-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-01